Compare Citius Pharmaceuticals Inc (CTXR) vs L3Harris Technologies Inc (LHX) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

LHX trades at $288.69, down 0.72% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $2.72, beating estimates of $2.53, continuing a trend of earnings beats. Revenue grew to $21.87 billion in 2025, with net income margin improving to 7.34%. Recent contract wins include a U.S. Space Force satellite deal and U.S. Army communications orders, supporting growth prospects.

The outlook remains positive with a consensus price target of $367.50, implying 27% upside, and 75% of analysts rate it a Buy. Risks include execution on record $40.7 billion backlog, debt levels, and defense budget volatility. The stock offers dividend income with a $1.25 quarterly payout, balancing growth and income appeal for investors.